THW abrdn World Healthcare Fund

Portfolio of Investments (unaudited) 
As of June 30, 2024

abrdn World Healthcare Fund

Portfolio of Investments (unaudited)  (continued)
As of June 30, 2024

abrdn World Healthcare Fund

See accompanying Notes  to Portfolio of Investments.

Portfolio of Investments (unaudited)  (continued)
As of June 30, 2024

abrdn World Healthcare Fund

At June 30, 2024, the Fund held the following forward foreign currency contracts:

    

Sale Contracts Settlement Date	Counterparty		Currency Purchased	Amount Purchased	Currency Sold	Amount Sold	Fair Value	Unrealized Appreciation/ (Depreciation)
United States Dollar/Australian Dollar
07/31/2024	Goldman Sachs & Co.		USD	3,052,589	AUD	4,572,304	$3,052,587	$2
United States Dollar/British Pound
07/31/2024	Goldman Sachs & Co.		USD	15,011,411	GBP	11,829,575	14,956,305	55,106
United States Dollar/Danish Krone
07/31/2024	Goldman Sachs & Co.		USD	17,463,796	DKK	121,150,489	17,425,729	38,067
United States Dollar/Euro
07/31/2024	Goldman Sachs & Co.		USD	22,000,111	EUR	20,467,143	21,949,205	50,906
United States Dollar/Israeli Shekel
07/31/2024	Goldman Sachs & Co.		USD	1,198,427	ILS	4,457,647	1,181,549	16,878
United States Dollar/Japanese Yen
07/31/2024	Goldman Sachs & Co.		USD	3,298,337	JPY	523,322,125	3,267,037	31,300
United States Dollar/Swiss Franc
07/31/2024	Goldman Sachs & Co.		USD	15,602,264	CHF	13,872,816	15,494,713	107,551
							$77,327,125	$299,810

    

See accompanying Notes  to Portfolio of Investments.

Portfolio of Investments (unaudited)  (concluded)
As of June 30, 2024

abrdn World Healthcare Fund

	Number of Contracts (100 shares each)	Notional Amount ($)	Value ($)
Option Contracts Written—(0.1)%
Call Options Written—(0.1)%
Amgen, Inc. Jul24 320 Call	19	(608,000)	(1,596)
Ardelyx, Inc. Jul24 7 Call	1,275	(892,500)	(95,625)
Argenx SE Jul24 470 Call	13	(611,000)	(1,820)
Becton Dickinson & Co. Jul24 240 Call	25	(600,000)	(4,550)
Biogen, Inc. Jul24 225 Call	27	(607,500)	(23,085)
Biogen, Inc. Jul24 240 Call	77	(1,848,000)	(15,400)
Boston Scientific Corp. Jul24 80 Call	75	(600,000)	(2,250)
Charles River Laboratories International, Inc. Jul24 220 Call	27	(594,000)	(4,455)
Danaher Corp. Jul24 260 Call	23	(598,000)	(575)
Dexcom, Inc. Jul24 115 Call	52	(598,000)	(5,616)
Elevance Health, Inc. Jul24 550 Call	22	(1,210,000)	(21,076)
Gilead Sciences, Inc. Jul24 71 Call	320	(2,272,000)	(2,240)
HCA Healthcare, Inc. Jul24 350 Call	17	(595,000)	(1,292)
IDEXX Laboratories, Inc. Jul24 520 Call	11	(572,000)	(2,882)
Insulet Corp. Jul24 210 Call	60	(1,260,000)	(18,600)
IQVIA Holdings, Inc. Jul24 220 Call	27	(594,000)	(6,156)
Medtronic PLC Jul24 82.5 Call	72	(594,000)	(936)
Merck & Co., Inc. Jul24 135 Call	44	(594,000)	(132)
Molina Healthcare, Inc. Jul24 310 Call	19	(589,000)	(4,750)
ResMed, Inc. Jul24 220 Call	27	(594,000)	(621)
Sanofi SA Jul24 47.5 Call	645	(3,063,750)	(135,450)
Stryker Corp. Jul24 350 Call	17	(595,000)	(3,060)
Teva Pharmaceutical Industries Ltd. Jul24 17 Call	352	(598,400)	(1,408)
UnitedHealth Group, Inc. Jul24 490 Call	24	(1,176,000)	(43,656)
Zoetis, Inc. Jul24 170 Call	35	(595,000)	(26,005)
Total Call Options Written (Premiums received $(278,902))			(423,236)

 

See accompanying Notes  to Portfolio of Investments.

Notes to Portfolio of Investments 
June 30, 2024 (unaudited)

1.    Summary of Significant Accounting Policies

a.    Security Valuation:

The Fund values its securities at current market value or fair value, consistent with regulatory requirements. "Fair value" is defined in the Fund's Valuation and Liquidity Procedures as the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between willing market participants without a compulsion to transact at the measurement date. Pursuant to Rule 2a-5 under the 1940 Act, the Board of Trustees (the "Board") designated abrdn as the valuation designee ("Valuation Designee") for the Fund to perform the fair value determinations relating to Fund investments for which market quotations are not readily available or deemed unreliable.

Long-term debt and other fixed-income securities are valued at the last quoted or evaluated bid price on the valuation date provided by an independent pricing service provider. If there are no current day bids, the security is valued at the previously applied bid. Pricing services generally price debt securities assuming orderly transactions of an institutional “round lot” size and the strategies employed by the Valuation Designee generally trade in round lot sizes. In certain circumstances, some trades may occur in smaller “odd lot” sizes which may be effected at lower, or higher, prices than institutional round lot trades. Short-term debt securities (such as commercial paper and U.S. treasury bills) having a remaining maturity of 60 days or less are valued at the last quoted or evaluated bid price on the valuation date provided by an independent pricing service, or on the basis of amortized cost, if it represents the best approximation of fair value. Debt and other fixed-income securities are generally determined to be Level 2 investments.

Equity securities that are traded on an exchange are valued at the last quoted sale price or the official close price on the principal exchange on which the security is traded at the “Valuation Time” subject to application, when appropriate, of the valuation factors described in the paragraph below. Under normal circumstances, the Valuation Time is as of the close of regular trading on the New York Stock Exchange ("NYSE") (usually 4:00 p.m. Eastern Time). In the absence of a sale price, the security is valued at the mean of the bid/ask price quoted at the close on the principal exchange on which the security is traded. Securities traded on NASDAQ are valued at the NASDAQ official closing price.

Convertible preferred shares, warrants or convertible note interests in Venture Capital Securities, milestone interests, and other restricted securities are typically valued in good faith, based upon the recommendations made by the PV Valuation Committee or the Valuation Designee pursuant to fair valuation policies and procedures approved by the Board.

Derivative instruments are valued at fair value. Exchange-traded futures are generally Level 1 investments and centrally cleared swaps and forwards are generally Level 2 investments. Forward foreign currency contracts are generally valued based on the bid price of the forward rates and the current spot rate. Forward exchange rate quotations are available for scheduled settlement dates, such as 1-, 3-, 6-, 9- and 12-month periods. An interpolated valuation is derived based on the actual settlement dates of the forward contracts held. Futures contracts are valued at the settlement price or at the last bid price if no settlement price is available. Swap agreements are generally valued by an approved pricing agent based on the terms of the swap agreement (including future cash flows). When market quotations or exchange rates are not readily available, or if the Adviser concludes that such market quotations do not accurately reflect fair value, the fair value of the Fund’s assets are determined in good faith in accordance with the Valuation Procedures.

Foreign equity securities that are traded on foreign exchanges that close prior to the Valuation Time are valued by applying valuation factors to the last sale price or the mean price as noted above. Valuation factors are provided by an independent pricing service provider. These valuation factors are used when pricing the Fund's portfolio holdings to estimate market movements between the time foreign markets close and the time the Fund values such foreign securities. These valuation factors are based on inputs such as depositary receipts, indices, futures, sector indices/ETFs, exchange rates, and local exchange opening and closing prices of each security. When prices with the application of valuation factors are utilized, the value assigned to the foreign securities may not be the same as quoted or published prices of the securities on their primary markets. A security that applies a valuation factor is generally determined to be a Level 2 investment because the exchange-traded price has been adjusted. Valuation factors are not utilized if the independent pricing service provider is unable to provide a valuation factor or if the valuation factor falls below a predetermined threshold.

Short-term investments are comprised of cash and cash equivalents invested in short-term investment funds which are redeemable daily. The Fund sweeps available cash into the State Street Institutional U.S. Government Money Market Fund, which has elected to qualify as a “government money market fund” pursuant to Rule 2a-7 under the 1940 Act, and has an objective, which is not guaranteed, to maintain a $1.00 per share NAV. Generally, these investment types are categorized as Level 1 investments.

In the event that a security’s, other than a Venture Capital Security, market quotations are not readily available or are deemed unreliable (for reasons other than because the foreign exchange on which it trades closes before the Valuation Time), the security is valued at fair value as determined by the Valuation Designee, taking into account the relevant factors and surrounding circumstances using valuation policies and procedures approved by the Board. A security that has been fair valued by the Adviser may be classified as Level 2 or Level 3 depending on the nature of the inputs.

5

Notes to Portfolio of Investments  (concluded)
June 30, 2024 (unaudited)

Venture Capital Securities are valued based on a consideration of relevant factors, including both observable and unobservable inputs. Observable and unobservable inputs considered may include (i) the existence of any contractual restrictions on the disposition of securities; (ii) information obtained from the company, which may include an analysis of the company's financial statements, products, intended markets or technologies; (iii) the price of the same or similar security negotiated at arm's length in an issuer's completed subsequent round of financing; (iv) the price and extent of public trading in similar securities of the issuer or of comparable companies; or (v) a probability and time value adjusted analysis of contractual terms. Where available and appropriate, multiple valuation methodologies are applied to confirm fair value. Significant unobservable inputs are often used in the fair value determination. A significant change in any of these inputs may result in a significant change in the fair value measurement. Additionally, changes in the market environment and other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different from the valuations used at the date of these financial statements.

In accordance with the authoritative guidance on fair value measurements and disclosures under U.S. GAAP, the Fund discloses the fair value of its investments using a three-level hierarchy that classifies the inputs to valuation techniques used to measure the fair value. The hierarchy assigns Level 1, the highest level, measurements to valuations based upon unadjusted quoted prices in active markets for identical assets, Level 2 measurements to valuations based upon other significant observable inputs, including adjusted quoted prices in active markets for similar assets, and Level 3, the lowest level, measurements to valuations based upon unobservable inputs that are significant to the valuation. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, for example, the risk inherent in a particular valuation technique used to measure fair value including a pricing model and/or the risk inherent in the inputs to the valuation technique. Inputs may be observable or unobservable. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability, which are based on market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. A financial instrument’s level within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement.

Open-end mutual funds are valued at the respective NAV as reported by such company. The prospectuses for the registered open-end management investment companies in which the Fund invests explain the circumstances under which those companies will use fair value pricing and the effects of using fair value pricing. Closed-end funds and exchange-traded funds (“ETFs”) are valued at the market price of the security at the Valuation Time (defined below). A security using any of these pricing methodologies is generally determined to be a Level 1 investment.

The three-level hierarchy of inputs is summarized below:

Level 1 - quoted prices (unadjusted) in active markets for identical investments;

Level 2 - other significant observable inputs (including valuation factors, quoted prices for similar securities, interest rates, prepayment speeds, and credit risk, etc.); or

Level 3 - significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments).

Level 3 investments are valued using significant unobservable inputs. The Fund may also use a discounted cash flow based valuation approach in which the anticipated future cash flows of the investment are used to estimate the current fair value. The derived value of a Level 3 investment may not represent the value which is received upon disposition and this could impact the results of operations. 

6